Cetuximab and biomarkers in non-small-cell lung carcinoma

References

• FerlayJShinHBrayFFormanDMathersCParkinDGLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10Lyon, FranceInternational Agency for Research on Cancer2010 http://globocan.iarc.fr. Accessed May 24, 2011.
   Google Scholar
• FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer2010127122893291721351269
   PubMed Web of Science ®Google Scholar
• LaskinJJSandlerABJohnsonDHNon-Small Cell Lung CancerPhiladelphia, PASaunders2005
   Google Scholar
• AlbergAJBrockMVSametJMEpidemiology of lung cancer: looking to the futureJ Clin Oncol200523143175318515886304
   PubMed Web of Science ®Google Scholar
• VineisPAiroldiLVegliaFEnvironmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective studyBMJ2005330748627715681570
   PubMed Web of Science ®Google Scholar
• TardonALeeWJDelgado-RodriguezMLeisure-time physical activity and lung cancer: a meta-analysisCancer Causes Control200516438939715953981
   PubMed Web of Science ®Google Scholar
• LeeIMPhysical activity and cancer prevention – data from epidemiologic studiesMed Sci Sports Exerc200335111823182714600545
   PubMed Web of Science ®Google Scholar
• BoffettaPEpidemiology of environmental and occupational cancerOncogene200423386392640315322513
   PubMed Web of Science ®Google Scholar
• MolinaJRYangPCassiviSDSchildSEAdjeiAANon-small cell lung cancer: epidemiology, risk factors, treatment, and survivorshipMayo Clin Proc200883558459418452692
   PubMed Web of Science ®Google Scholar
• BarlesiFJacotWAstoulPPujolJLSecond-line treatment for advanced non-small cell lung cancer: a systematic reviewLung Cancer200651215917216360238
   PubMed Web of Science ®Google Scholar
• MokTSWuYLYuCJRandomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancerJ Clin Oncol200927305080508719738125
   PubMed Web of Science ®Google Scholar
• OkamotoIEpidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapyFEBS J2010277230931519922468
   PubMed Web of Science ®Google Scholar
• MendelsohnJBaselgaJStatus of epidermal growth factor receptor antagonists in the biology and treatment of cancerJ Clin Oncol200321142787279912860957
   PubMed Web of Science ®Google Scholar
• BrabenderJDanenbergKDMetzgerREpidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survivalClin Cancer Res2001771850185511448895
   PubMed Web of Science ®Google Scholar
• BiancoRGelardiTDamianoVCiardielloFTortoraGMechanisms of resistance to EGFR inhibitorsTarget Oncol2007213137
   Web of Science ®Google Scholar
• SalomonDSBrandtRCiardielloFNormannoNEpidermal growth factor-related peptides and their receptors in human malignanciesCrit Rev Oncol Hematol19951931832327612182
   PubMed Web of Science ®Google Scholar
• CiardielloFTortoraGEGFR antagonists in cancer treatmentN Engl J Med2008358111160117418337605
   PubMed Web of Science ®Google Scholar
• NormannoNTejparSMorgilloFDeLAVanCECiardielloFImplications for KRAS status and EGFR-targeted therapies in metastatic CRCNat Rev Clin Oncol20096951952719636327
   PubMed Web of Science ®Google Scholar
• YardenYSliwkowskiMXUntangling the ErbB signalling networkNat Rev Mol Cell Biol20012212713711252954
   PubMed Web of Science ®Google Scholar
• FergusonKMBergerMBMendrolaJMChoHSLeahyDJLemmonMAEGF activates its receptor by removing interactions that autoinhibit ectodomain dimerizationMol Cell200311250751712620237
   PubMed Web of Science ®Google Scholar
• BurgessAWChoHSEigenbrotCAn open-and-shut case? Recent insights into the activation of EGF/ErbB receptorsMol Cell200312354155214527402
   PubMed Web of Science ®Google Scholar
• KingACCuatrecasasPResolution of high and low affinity epidermal growth factor receptors. Inhibition of high affinity component by low temperature, cycloheximide, and phorbol estersJ Biol Chem19822576305330606277923
   PubMed Web of Science ®Google Scholar
• SchlessingerJLigand-induced, receptor-mediated dimerization and activation of EGF receptorCell2002110666967212297041
   PubMed Web of Science ®Google Scholar
• TannerKGKyteJDimerization of the extracellular domain of the receptor for epidermal growth factor containing the membrane-spanning segment in response to treatment with epidermal growth factorJ Biol Chem199927450359853599010585488
   PubMed Web of Science ®Google Scholar
• BargmannCIHungMCWeinbergRAMultiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185Cell19864556496572871941
   PubMed Web of Science ®Google Scholar
• BennasrouneAFickovaMGardinATransmembrane peptides as inhibitors of ErbB receptor signalingMol Biol Cell20041573464347415146055
   PubMed Web of Science ®Google Scholar
• MorikiTMaruyamaHMaruyamaINActivation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domainJ Mol Biol200131151011102611531336
   PubMed Web of Science ®Google Scholar
• BellCATynanJAHartKCMeyerANRobertsonSCDonoghueDJRotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinaseMol Biol Cell200011103589359911029057
   PubMed Web of Science ®Google Scholar
• WaltonGMChenWSRosenfeldMGGillGNAnalysis of deletions of the carboxyl terminus of the epidermal growth factor receptor reveals self-phosphorylation at tyrosine 992 and enhanced in vivo tyrosine phosphorylation of cell substratesJ Biol Chem19902653175017541688559
   PubMed Web of Science ®Google Scholar
• SchlessingerJCell signaling by receptor tyrosine kinasesCell2000103221122511057895
   PubMed Web of Science ®Google Scholar
• StamosJSliwkowskiMXEigenbrotCStructure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitorJ Biol Chem200227748462654627212196540
   PubMed Web of Science ®Google Scholar
• WeberWBerticsPJGillGNImmunoaffinity purification of the epidermal growth factor receptor. Stoichiometry of binding and kinetics of self-phosphorylationJ Biol Chem19842592314631146366094567
   PubMed Web of Science ®Google Scholar
• FergusonKMActive and inactive conformations of the epidermal growth factor receptorBiochem Soc Trans200432Pt 574274515494003
   PubMed Web of Science ®Google Scholar
• NishibeSCarpenterGTyrosine phosphorylation and the regulation of cell growth: growth factor-stimulated tyrosine phosphorylation of phospholipase CSemin Cancer Biol1990142852922103503
   PubMedGoogle Scholar
• AkiyamaTKadowakiTNishidaESubstrate specificities of tyrosine-specific protein kinases toward cytoskeletal proteins in vitroJ Biol Chem19862613114797148033771552
   PubMed Web of Science ®Google Scholar
• SubrahmanyamGBerticsPJAndersonRAPhosphorylation of protein 4.1 on tyrosine-418 modulates its function in vitroProc Natl Acad Sci U S A19918812522252261647028
   PubMed Web of Science ®Google Scholar
• HeisermannGJGillGNEpidermal growth factor receptor threonine and serine residues phosphorylated in vivoJ Biol Chem19882632613152131583138233
   PubMed Web of Science ®Google Scholar
• DownwardJParkerPWaterfieldMDAutophosphorylation sites on the epidermal growth factor receptorNature198431159854834856090945
   PubMed Web of Science ®Google Scholar
• HunterTLingNCooperJAProtein kinase C phosphorylation of the EGF receptor at a threonine residue close to the cytoplasmic face of the plasma membraneNature198431159854804836090944
   PubMed Web of Science ®Google Scholar
• SatoKSatoAAotoMFukamiYc-Src phosphorylates epidermal growth factor receptor on tyrosine 845Biochem Biophys Res Commun19952153107810877488034
   PubMed Web of Science ®Google Scholar
• BarbierAJPoppletonHMYigzawYTransmodulation of epidermal growth factor receptor function by cyclic AMP-dependent protein kinaseJ Biol Chem199927420140671407310318821
   PubMed Web of Science ®Google Scholar
• DaubHWeissFUWallaschCUllrichARole of transactivation of the EGF receptor in signalling by G-protein-coupled receptorsNature199637965655575608596637
   PubMed Web of Science ®Google Scholar
• ZwickEHackelPOPrenzelNUllrichAThe EGF receptor as central transducer of heterologous signalling systemsTrends Pharmacol Sci1999201040841210577253
   PubMed Web of Science ®Google Scholar
• ScaltritiMBaselgaJThe epidermal growth factor receptor pathway: a model for targeted therapyClin Cancer Res200612185268527217000658
   PubMed Web of Science ®Google Scholar
• OdaKMatsuokaYFunahashiAKitanoHA comprehensive pathway map of epidermal growth factor receptor signalingMol Syst Biol20051200516729045
   PubMed Web of Science ®Google Scholar
• KolchWPittAFunctional proteomics to dissect tyrosine kinase signalling pathways in cancerNat Rev Cancer201010961862920720570
   PubMed Web of Science ®Google Scholar
• MascauxCIanninoNMartinBThe role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysisBr J Cancer200592113113915597105
   PubMed Web of Science ®Google Scholar
• ShieldsJMPruittKMcFallAShaubADerCJUnderstanding Ras: ‘It ain’t over ‘til it’s over’Trends Cell Biol200010414715410740269
   PubMed Web of Science ®Google Scholar
• RodenhuisSSlebosRJClinical significance of ras oncogene activation in human lung cancerCancer Res199252Suppl 92665s2669s1562997
   PubMed Web of Science ®Google Scholar
• PaoWWangTYRielyGJKRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinibPLoS Med200521e1715696205
   PubMed Web of Science ®Google Scholar
• EberhardDAJohnsonBEAmlerLCMutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinibJ Clin Oncol200523255900590916043828
   PubMed Web of Science ®Google Scholar
• RielyGJKrisMGRosenbaumDFrequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinomaClin Cancer Res200814185731573418794081
   PubMed Web of Science ®Google Scholar
• SunSSchillerJHGazdarAFLung cancer in never smokers – a different diseaseNat Rev Cancer200771077879017882278
   PubMed Web of Science ®Google Scholar
• VivancoISawyersCLThe phosphatidylinositol 3-kinase AKT pathway in human cancerNat Rev Cancer20022748950112094235
   PubMed Web of Science ®Google Scholar
• YamamotoHShigematsuHNomuraMPIK3CA mutations and copy number gains in human lung cancersCancer Res200868176913692118757405
   PubMed Web of Science ®Google Scholar
• SoriaJCLeeHYLeeJILack of PTEN expression in non-small cell lung cancer could be related to promoter methylationClin Cancer Res2002851178118412006535
   PubMed Web of Science ®Google Scholar
• MarsitCJZhengSAldapeKPTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alterationHum Pathol200536776877616084946
   PubMed Web of Science ®Google Scholar
• YuHPardollDJoveRSTATs in cancer inflammation and immunity: a leading role for STAT3Nat Rev Cancer200991179880919851315
   PubMed Web of Science ®Google Scholar
• DarnellJEJrSTATs and gene regulationScience19972775332163016359287210
   PubMed Web of Science ®Google Scholar
• YuHJoveRThe STATs of cancer – new molecular targets come of ageNat Rev Cancer2004429710514964307
   PubMed Web of Science ®Google Scholar
• KimLCSongLHauraEBSrc kinases as therapeutic targets for cancerNat Rev Clin Oncol200961058759519787002
   PubMed Web of Science ®Google Scholar
• AggarwalBBKunnumakkaraABHarikumarKBSignal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?Ann N Y Acad Sci20091171597619723038
   PubMed Web of Science ®Google Scholar
• GantiAKEpidermal growth factor receptor signaling in nonsmall cell lung cancerCancer Invest201028551552520073576
   PubMed Web of Science ®Google Scholar
• Sanchez-CejaSGReyes-MaldonadoEVazquez-ManriquezMELopez-LunaJJBelmontAGutierrez-CastellanosSDifferential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinomaLung Cancer200654216316816959370
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
   PubMed Web of Science ®Google Scholar
• MendelsohnJKawamotoHybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor United States Patent: 4,943,533.7201990
   Google Scholar
• HumbletYCetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumoursExpert Opin Pharmacother2004571621163315212612
   PubMed Web of Science ®Google Scholar
• GoldsteinNIPrewettMZuklysKRockwellPMendelsohnJBiological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft modelClin Cancer Res1995111131113189815926
   PubMed Web of Science ®Google Scholar
• HsuYFAjonaDCorralesLComplement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivoMol Cancer2010913920529262
   PubMed Web of Science ®Google Scholar
• RansonMSliwkowskiMXPerspectives on anti-HER monoclonal antibodiesOncology200263Suppl 1172412422051
   PubMed Web of Science ®Google Scholar
• AtkinsonAJColburnWADeGruttolaVGBiomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClin Pharmacol Ther2001693899511240971
   PubMed Web of Science ®Google Scholar
• ButtsCABodkinDMiddlemanELRandomized phase II study of gemcitabine plus cisplatin or carboplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small-cell lung cancerJ Clin Oncol200725365777578418089875
   PubMed Web of Science ®Google Scholar
• RosellRRobinetGSzczesnaARandomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancerAnn Oncol200819236236917947225
   PubMed Web of Science ®Google Scholar
• LynchTJPatelTDreisbachLCetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099J Clin Oncol201028691191720100966
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb, ImClone LLCStudy of taxane/carboplatin +/– cetuximab as first-line treatment for patients with advanced/metastatic non-small cell lung cancerNCT001122942012 Available from: http://clinicaltrials.gov/show/NCT00112294. Accessed on June 18, 2012.
   Google Scholar
• Khambata-FordSHarbisonCTHartLLAnalysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancerJ Clin Oncol201028691892720100958
   PubMed Web of Science ®Google Scholar
• HannaNLilenbaumRAnsariRPhase II trial of cetuximab in patients with previously treated non-small-cell lung cancerJ Clin Oncol200624335253525817114658
   PubMed Web of Science ®Google Scholar
• PirkerRPereiraJRvonPJEGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX studyLancet Oncol2012131334222056021
   PubMed Web of Science ®Google Scholar
• HirschFRHerbstRSOlsenCIncreased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapyJ Clin Oncol200826203351335718612151
   PubMed Web of Science ®Google Scholar
• LinHJiangJLiangXZhouXHuangRChemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysisLung Cancer2010701576220149474
   PubMed Web of Science ®Google Scholar
• AmadoRGWolfMPeetersMWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol200826101626163418316791
   PubMed Web of Science ®Google Scholar
• FransenKKlintenasMOsterstromADimbergJMonsteinHJSoderkvistPMutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomasCarcinogenesis200425452753314688025
   PubMed Web of Science ®Google Scholar
• DeRWPiessevauxHDeSJKRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximabAnn Oncol200819350851517998284
   PubMed Web of Science ®Google Scholar
• DiFFBlanchardFCharbonnierFClinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapyBr J Cancer20079681166116917375050
   PubMed Web of Science ®Google Scholar
• KosakaTYatabeYEndohHKuwanoHTakahashiTMitsudomiTmutations of the epidermal growth factor receptor gene in lung cancerCancer Res200464248919892315604253
   PubMed Web of Science ®Google Scholar
• TamIYSChungLPSuenWSDistinct epidermal growth factor receptor and kras mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic featuresClin Cancer Res20061251647165316533793
   PubMed Web of Science ®Google Scholar
• O’ByrneKJGatzemeierUBondarenkoIMolecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX studyLancet Oncol201112879580521782507
   PubMed Web of Science ®Google Scholar
• HerbstRSKellyKChanskyKPhase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342J Clin Oncol201028314747475420921467
   PubMed Web of Science ®Google Scholar
• MerckKGaAStudy of cisplatin/vinorelbine +/– cetuximab as First-line treatment of advanced non-small cell lung cancer (FLEX)NCT001487982012 Available from: http://clinicaltrials.gov/ct2/show/NCT00148798?term=NCT00148798&rank=1. Accessed on June 18, 2012.
   Google Scholar
• NikolovaDAAsanganiIANelsonLDFetuximab attenuates metastasis and u-PAR eExpression in non-small cell lung cancer: u-PAR and E-Cadherin are novel biomarkers of cetuximab sensitivityCancer Res20096962461247019276367
   PubMed Web of Science ®Google Scholar
• YonesakaKZejnullahuKOkamotoIActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximabSci Transl Med201139999ra86
   PubMed Web of Science ®Google Scholar
• YonesakaKZejnullahuKLindemanNAutocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancersClin Cancer Res200814216963697318980991
   PubMed Web of Science ®Google Scholar
• WuJYYangCHHsuYCUse of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancerClin Lung Cancer201011425726320630828
   PubMed Web of Science ®Google Scholar
• PaezJGJannePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience200430456761497150015118125
   PubMed Web of Science ®Google Scholar
• PaoWMillerVZakowskiMEGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProc Natl Acad Sci U S A200410136133061331115329413
   PubMed Web of Science ®Google Scholar
• HuangSFLiuHPLiLHHigh frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in TaiwanClin Cancer Res200410248195820315623594
   PubMed Web of Science ®Google Scholar
• HerbstRSGiacconeGSchillerJHGefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2J Clin Oncol200422578579414990633
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med2004350212129213915118073
   PubMed Web of Science ®Google Scholar
• MukoharaTEngelmanJAHannaNHDifferential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutationsJ Natl Cancer Inst200597161185119416106023
   PubMedGoogle Scholar
• VanCEKohneCHHitreECetuximab and chemotherapy as initial treatment for metastatic colorectal cancerN Engl J Med2009360141408141719339720
   PubMed Web of Science ®Google Scholar
• TolJKoopmanMCatsAChemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancerN Engl J Med2009360656357219196673
   PubMed Web of Science ®Google Scholar
• LurjeGLenzHJEGFR signaling and drug discoveryOncology200977640041020130423
   PubMed Web of Science ®Google Scholar
• GovindanRCetuximab in advanced non-small cell lung cancerClin Cancer Res20041012 Pt 24241s4244s15217966
   PubMed Web of Science ®Google Scholar
• PennellNALynchTJJrCombined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLCOncologist200914439941119357226
   PubMed Web of Science ®Google Scholar
• KruserTJWheelerDLMechanisms of resistance to HER family targeting antibodiesExp Cell Res201031671083110020064507
   PubMed Web of Science ®Google Scholar
• RossiABriaEMaionePPalazzoloGFalangaMGridelliCThe role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancerRev Recent Clin Trials20083321722718782080
   PubMedGoogle Scholar
• CapdevilaJElezEMacarullaTRamosFJRuiz-EcharriMTaberneroJAnti-epidermal growth factor receptor monoclonal antibodies in cancer treatmentCancer Treat Rev200935435436319269105
   PubMed Web of Science ®Google Scholar
• CiardielloFDeVFOrdituraMTortoraGThe role of EGFR inhibitors in non-small cell lung cancerCurr Opin Onco2004162130135
   Web of Science ®Google Scholar
• BrandTMIidaMLiCWheelerDLThe nuclear epidermal growth factor receptor signaling network and its role in cancerDiscov Med2011126641943222127113
   PubMed Web of Science ®Google Scholar